A carregar...
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
BACKGROUND: Ubrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine. This trial evaluated the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosi...
Na minha lista:
| Publicado no: | Cephalalgia |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6900570/ https://ncbi.nlm.nih.gov/pubmed/31537107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102419869918 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|